We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ADMA Biologics, Inc. is one of the best biotech stocks to invest in.
TheFly reported on April 21 that Canaccord Genuity initiated coverage of ADMA with a Buy rating and set a price target of $21. The firm highlighted an attractive risk-reward profile at current valuation levels. It noted that recent weakness in the stock has been driven by investor concerns over revenue recognition and the underlying demand trends for the company’s primary IVIG therapy, Asceniv. However, management commentary, along with positive feedback from key clinical stakeholders, was viewed as supportive of continued revenue growth and improving profitability trends going forward.
Linked to that, on March 27, ADMA Biologics, Inc. (NASDAQ:ADMA) issued a detailed response addressing claims made in a recent short-seller report, stating that the allegations were misleading and not supported by its operational and commercial data. The company emphasized that demand for its immune globulin products, including ASCENIV, continues to grow based on information from distributors and direct customers, with inventory and usage patterns indicating ongoing product pull-through rather than channel distortion.
ADMA also explained that distributor stocking levels reflect standard industry practices to ensure supply continuity for immunocompromised patients and maintain cold-chain stability. Additionally, the company reiterated that its financial reporting has received unqualified audit opinions for fiscal years 2024 and 2025 and confirmed compliance with accounting standards and internal control requirements, while denying any improper related-party transactions.
ADMA Biologics, Inc. (NASDAQ:ADMA) is an AI-enabled biopharmaceutical company specializing in plasma-derived therapies for immune deficiencies and infectious diseases. It uses its ADMAlytics platform to optimize plasma collection, manufacturing efficiency, and supply chain operations through data analytics and machine learning.
While we acknowledge the risk and potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADMA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
